Havana, Oct 23 – The development of natural products applied to humans in Cuba is among the topics to be debated today at the 20th Latin American Congress on Pharmacology and Therapeutics (Latinfarma) 2013, which is in session in Havana with the participation of 800 delegates from about 40 nations. The event, held at Havana´s Convention Center, has arranged for today the presentation of the results of peptide RJLB-14 in the treatment of patients with epithelial tumors.
Dr. Alexis Díaz-García and other scientists from the business group of biopharmaceutical labs (LABIOFAM) will present the potential of this compound for treating metastatic breast cancer. Its preclinical assessment has verified a high effectiveness rate, a dose-response relation, and its influence in the reduction of tumors; although they are still working on determining toxicity and action mechanism.
In addition, the State Center for Controlling Drugs and Medical Equipment will offer a dissertation on the economic implications of the consumption and safety of drugs; whereas other foreign experts will debate on cancer vaccines and natural products for the treatment of anti-inflammatory ailments.
For the fist time Cuba is the venue for the Latinfarma Latin American Congress, which is held in parallel with the 5th Ibero-American Congress on Pharmacology, the 11th National Congress and the 5th International Congress in that field.